胸腺肽α1辅助治疗肝硬化自发性腹膜炎患者的临床观察  

Clinical Study of Thymosin α1 to Treat Spontaneous Bacterial Peritonitis Accompanying Hepatocirrhosis

作　　者：王莹[1] 那琳琳[1] 张莉[1] 

机构地区：[1]哈尔滨二四二医院,黑龙江哈尔滨150060

出　　处：《哈尔滨医药》2012年第2期94-95,共2页Harbin Medical Journal

摘　　要：目的观察胸腺肽α1辅助治疗肝硬化自发性腹膜炎患者的临床疗效。方法选择38例肝硬化自发性腹膜炎患者,采用完全随机、对照的方法分成两组。胸腺肽治疗组19例,在保肝、退黄、利尿、抗感染等综合治疗基础上,同时皮下注射胸腺肽α1 1.6 mg,隔天1次,连用二周。对照组19例,仅给保肝、退黄、利尿、抗感染等综合治疗。结果胸腺肽治疗组对自发性腹膜炎的控制、稳定病情及疗效,显著优于对照组。结论胸腺肽α1辅助治疗肝硬化自发性腹膜炎患者的疗效优于常规综合治疗。Objective The efficacy of thymosinα1 in combination with conventional therapies was investigated in treatment of spontaneous bacterial peritonitis accompanying hepatocirrhosis.Methods In this study,38 patients were randomly divided into two groups,treatment and control groups.The treatment group of 19 cases received 1.6 mg thymosinα1 subcutaneous injections every other day for two weeks on the basis of nourishing the liver,jaundice,diuretic,anti-infective and other treatment,whereas the control group of 19 cases did not.Results The peritonitis was controlled and improved significantly in the thymosinα1-treated patients compared to controls.Conclusion Thymosinα1 may be conducive to treat spontaneous bacterial peritonitis accompanying hepatocirrhosis.

关 键 词：肝硬化 自发性腹膜炎 胸腺肽Α1 

分 类 号：R575.2[医药卫生—消化系统]